The Hub will address the manufacturing, business and regulatory challenges to ensure that new targeted biological medicines can be developed quickly and manufactured at a cost affordable to society.
The Future Targeted Healthcare Manufacturing Hub is supported by over 40 partnering companies and organisations with interests in the sector, to revolutionise the delivery of cost-effective stratified protein-based and personalised cell-based therapies to patients. Representatives are invited to meet twice a year as the Hub User Steering Committee (USC) to provide advice and guidance on the overall direction and progress of the Hub research programme.
In addition, there are 5 Specialist Working Groups (SWGs) for members to engage around key research themes in more detail and provide technical-level advice and steer:
- Digital Decisional Tools
- Cell-free Synthesis
- ATMP Manufacturing
- Regulatory Strategies, Reimbursement and Policy
Hub User Steering Committee Members*:
Companies: 3M, Adaptimmune Therapeutics, Aglaris, Albumedix, Allergan, Applikon Biotechnology, AstraZeneca, Autolus, BIA Separations, Biologic B, BioPharm Services, deltaDOT, Eli Lilly, Fujifilm Diosynth Biotechnologies, GSK, Ipsen, Kymab, Kuopio Centre for Cell and Gene Therapy, Lonza, Orchard Therapeutics, Oxford BioMedica, Pall, Perceptive, Puridify, Purolite, ReNeuron, Sartorius, SSC Bio, Sutro BioPharma, Tillingbourne Consulting, TrakCel, Univercells, West Pharmaceutical Services, Wyatt Technology
Industry/Govt Associations/Charities: ABPI, BIA, Cancer Research UK, KTN, LGC, MMIP, NIBSC
Translational Spokes: Cell and Gene Therapy Catapult, Centre for Process Innovation/NBMC
* Signatories of the Collaboration agreement at April 2021